HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: Chanel

This article was originally published in The Rose Sheet

Executive Summary

Chanel: Spring 1997 color collection features "natural and young, clean and fresh" shades, the company said. Chanel Levres Lumiere Neon lip glow provides "high-shine gloss effects," Chanel said. A four-color compact features Violet, Pink, Gold and Bronze Glow for $47.50. Other lip shades in the collection include Hydrabase creme lipstick in Beige Whisper for $20 and Hydracaresse super hydrating lipstick in Apricot Beige for $22.50. For the eyes, Intensites D'Ombre basic eye color is extended with an Apricot/Brass/Jet trio, priced at $40. Chanel's cheek addition is Joues Contraste powder blush in Golden Beige, priced at $35. For the nails, Le Vernis colors include Gold and Pure Pink, for $15 each. The collection will be available in February...

You may also be interested in...



Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel